• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Novo Nordisk A/S Common Stock (NY:NVO)

    40.30 -1.88 (-4.46%)
    Official Closing Price Updated: 7:00 PM EST, Nov 5, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Novo Nordisk A/S Common Stock

    < Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
    News headline image
    Peptide Therapies Are Changing the Future of Medicine — And the Market Could Reach $335 Billion
    Growing Demand for Next-Generation Therapies Is Putting Peptide Innovation at the Center of Healthcare's Biggest Growth Markets 
    From FN Media
    Via GlobeNewswire
    News headline image
    Peptide Therapies Are Changing the Future of Medicine — And the Market Could Reach $335 Billion
    EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(OTCQX:RHHBY),(NYSE:NVO),(NASDAQ:VKTX),(NYSE:LLY) EQNX::TICKER_END 
    Via FinancialNewsMedia
    News headline image
    The $294 Billion Peptide Boom: Biotech Companies Positioned for the Next Wave of Growth
    Breakthroughs in obesity, diabetes, oncology, and targeted therapies are driving fresh interest in peptide-based medicines and the companies developing the next generation of treatments. 
    From FN Media
    Via GlobeNewswire
    News headline image
    The $294 Billion Peptide Boom: Biotech Companies Positioned for the Next Wave of Growth
    EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NYSE:NVO),(NYSE:HIMS),(NYSE:ENHA),(NYSE:LLY) EQNX::TICKER_END 
    Via FinancialNewsMedia
    News headline image
    A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
    From Equity Insider
    Via GlobeNewswire
    News headline image
    Next-Generation Diabetes Therapies Are Reshaping Healthcare and Creating MultiBillion-Dollar Revenue Opportunities
    EQNX::TICKER_START (OTCQB:AVAI),(NYSE:NVO),(NASDAQ:SNY),(NASDAQ:DXCM),(NASDAQ:TNDM) EQNX::TICKER_END 
    Via FinancialNewsMedia
    News headline image
    Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
    EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NYSE:MMA),(NYSE:NVO),(NYSE:HIMS),(NYSE:LLY) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Topics Government
    News headline image
    Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
    Analysts project billions in future market value as biotech innovation and consumer demand continue driving the next wave of health performance products 
    From MarketNewsUpdates.com
    Via GlobeNewswire
    News headline image
    Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates
    EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NYSE:PFE),(NYSE:NVO),(NYSE:HIMS),(NYSE:LLY) EQNX::TICKER_END 
    Via FinancialNewsMedia
    News headline image
    Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates
    Next-generation wellness platforms targeting longevity, metabolism, and performance continue gaining momentum in one of healthcare’s fastest-growing sectors 
    From MarketNewsUpdates.com
    Via GlobeNewswire
    BioMedNewsBreaks — SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Advances Next-Generation GLP-1 Candidate as Obesity Drug Market Expands Rapidly
    Via Investor Brand Network
    The Next Generation of the GLP-1 Revolution Is Already Underway
    Via Investor Brand Network
    News headline image
    The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
    From stem cell therapies for frailty to α-Klotho protein programs and GLP-1 drug classes now labeled "longevity therapeutics," the science and the capital have finally met 
    From Equity Insider
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    The Next Generation of the GLP-1 Revolution Is Already Underway
    From BioMedWire
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    Novo Nordisk A/S Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – NVO
    From The DJS Law Group
    Via Business Wire
    News headline image
    NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    News headline image
    From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes
    Issued on behalf of Avant Technologies Inc. 
    From USA News Group
    Via GlobeNewswire
    News headline image
    FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
    From Faruqi & Faruqi, LLP
    Via Business Wire
    News headline image
    Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Novo Nordisk A/S (NVO) Shareholders
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Fraud Lawsuit
    News headline image
    Levi &amp; Korsinsky Announces the Filing of a Securities Class Action on Behalf of Novo Nordisk A/S (NVO) Shareholders
    Via TheNewswire.com
    Topics Fraud Lawsuit
    News headline image
    Deadline Soon: Novo Nordisk A/S (NVO) Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
    From The Law Offices of Frank R. Cruz
    Via Business Wire
    News headline image
    NOVO URGENT DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urges Novo Nordisk Investors to Contact the Firm Before September 30th
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    Contact Levi &amp; Korsinsky by September 30, 2025 Deadline to Join Class Action Against Novo Nordisk A/S (NVO)
    Via TheNewswire.com
    Topics Fraud Lawsuit
    News headline image
    Contact Levi & Korsinsky by September 30, 2025 Deadline to Join Class Action Against Novo Nordisk A/S (NVO)
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Fraud Lawsuit
    News headline image
    Investors Who Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi & Korsinsky About Pending Class Action - NVO
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Fraud Lawsuit
    News headline image
    Investors Who Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi &amp; Korsinsky About Pending Class Action - NVO
    Via TheNewswire.com
    Topics Fraud Lawsuit
    News headline image
    Novo Nordisk A/S Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – NVO
    From DJS Law Group
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.